АСЕ/ADA Inpatient Diabetes and Glycemie Control Consensus ConferenceClinical Effects of Hyperglycemia in the Cardiac Surgery Population: The Portland Diabetic Project
Section snippets
INTRODUCTION
At the time of this writing (in early 2006), the fact that acute hyperglycemia in hospitalized diabetic patients leads to poor in-hospital outcomes has been fairly well established (1., 2., 3., 4.). Our early work on this subject, which began in 1987, and continues today is known as the Portland Diabetic Project. This ongoing study is a prospective nonrandomized study of the effects of hyperglycemia, and its pharmacologic reduction with intensive intravenous insulin regimens, on outcomes in the
METHODS AND DEMOGRAPHICS
All cardiac surgery patients who were operated on at St. Vincent Medical Center between 1987 and 2005, and those who were either admitted or discharged with the diagnosis of “diabetes,” were enrolled in the Portland Diabetic Project. Of the 23,619 patients operated on during this period, 5,510 (23% of the overall open heart surgery population at this center) met these inclusion criteria and were entered into the study. The average age was 65 ± 10 years; 70% of the population was male, and 12%
Glycemic Control
The average 3-BG over time for all 5,510 patients in the study is shown in scattergram form (Fig. 1). As can be seen from this figure, glycemic control improved gradually and steadily over time. Interestingly, it continues to do so as both floor and ICU nurses have become used to the concept of total glycemic control, driving patients into the lower reaches of the specified target ranges. The average 3-BG for all 299 diabetic cardiac surgery patients in calendar year 2005 was 121 mg/dL.
Mortality
In the
DURATION OF 3-BG EFFECT AND CII THERAPY ON OUTCOMES
Detailed multivariable analyses of the interrelationship between the various components of 3-BG and LOS, mortality, and DSWI were performed to determine the time-related impact of hyperglycemia on these outcomes. A summary of these findings is shown in Table 1. Results showed that hyperglycemia on the day of surgery, and the first and second postoperative days, significantly affects mortality. Hyperglycemia also has a significant affect on DSWI outcomes throughout the perioperative period
CONCLUSION
Our data suggest that diabetes itself is not a risk factor for adverse outcomes following cardiac surgery. Rather, hyperglycemia, as defined by 3-BG, is the true risk factor for increases in mortality, DSWI, LOS, and other complications. Importantly, both the “3” and the “BG” are essential components of that risk. Because of these findings, CII should become the accepted gold standard of care and should be utilized to maintain euglycemia for 3 full days in all hyperglycemic cardiac surgery
REFERENCES (6)
- et al.
Continuous insulin infusion reduces mortality in patients with diabetes undergoing coronary artery bypass grafting
J Thorac Cardiovasc Surg.
(2003) - et al.
Effect of hyperglycemia and continuous intravenous insulin infusions on outcomes of cardiac surgical procedures: the Portland Diabetic Project
EndocrPract.
(2004) - et al.
(American College of Endocrinology Task Force on Inpatient Diabetes Metabolic Control). American College of Endocrinology position statement on inpatient diabetes and metabolic control
Endocr Pract.
(2004)
Cited by (136)
Malglycemia in the critical care setting. Part III: Temporal patterns, relative potencies, and hospital mortality
2024, Journal of Critical CareNurse led protocols for control of glycaemia in critically ill patients: A systematic review
2022, Intensive and Critical Care NursingInpatient Diabetes Management
2022, Primary Care - Clinics in Office PracticeTargeted Glycemic Control for Adult Patients With Type 2 Diabetes Mellitus in the Acute Care Setting
2018, Canadian Journal of Diabetes